Longitudinal study of anti-myeloma treatment patterns in a U.S. commercial population before and after approval of bortezomib (BOR). The utility and prognostic value of positron emission tomography ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback